Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT | | | March 31, | December 31, | | --- | --- | --- | --- | | | | 2024 | 2023 | | | | (in thousands) | | | Assets | Notes | £ | £ | | Non-current assets | | | | | Intangible assets | 5 | 2,165 | 2,128 | | Property, plant and equipment | | 430 | 521 | | Deferred tax asset | 3 | 156 | 143 | | | | 2,751 | 2,792 | | Current assets | | | | | Prepayments, accrued ...

Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad clinical dev ...

Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled "Our focus remains on advancing our innovative ProTide pipeline to develop more efficacious and safer medicines for patients with cancer," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "NUC-3373, a transformation of 5-FU, is currently being investigated in three ongoing clinical studies. Our randomized Phase 2 study (NuTide:323) is now fully enrolle ...

EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), ("NuCana" or the "Company"), announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") and the matter is closed. As ann ...

As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT ...

Edinburgh, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. Exhibit 99.1 NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Ef icacy and Safety Pipeline Continues to ...

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | For the Three Months Ended | | For the Nine Months Ended | | | --- | --- | --- | --- | --- | --- | | | | September 30, | | September 30, | | | | Notes | 2023 | 2022 | 2023 | 2022 | | | | | (in thousands, except per share data) | | | | | | ਣ | | キ | ਦੇ | | Research and development expenses | | (7,439) | (7,386) | (18,203) | (23,238) | | Administrative expenses | | (1,375) | (1,715) | (4,777) | (5,756) | | Net foreign exch ...

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | For the Three Months Ended March 31, | | | --- | --- | --- | --- | | | Notes | 2023 | 2022 | | | | (in thousands, except per share data) | | | | | £ | £ | | Research and development expenses | | (6,805) | (9,446) | | Administrative expenses | | (1,648) | (2,152) | | Net foreign exchange (losses) gains | | (695) | 1,131 | | Operating loss | | (9,148) | (10,467) | | Finance income | | 287 | 31 | | Loss before tax | | (8,86 ...

A New Era in Oncology Limitations of Nucleoside Analogs Peak Year Sales 16 FDA Approved Anti-Cancer Nucleoside Drugs Activation Inefficient generation of anti-cancer metabolites 4 HIV Genvoya® 150 mg / 150 mg 200 mg / 10 mg film-coated tablets Elvitegravir/cobicistat/ Genvoya® emtricitabine/ tenofovir alafenamide 50 mg / 150 mg 30 film-coated tablets ericitabin Grail use (I GILEAD ¹ Sovaldi + Harvoni + Epclusa + Vosevi cumulative sales through 31 December 2022 2 Genvoya + Descovy + Odefsey + Biktarvy + Symt ...

As filed with the Securities and Exchange Commission on April 4, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT ...